Swedish Orphan Biovitrum extends Cyanokit cooperation

Published: 1-Apr-2010
Finance

Firm adds Ireland, the UK and The Netherlands to distribution territories


Swedish Orphan Biovitrum has expanded its agreement with Merck Serono, for the distribution of Cyanokit (hydroxocobalamin).

Under the agreement, the company will handle distribution in Ireland, UK and The Netherlands, in addition to the existing territories of the Nordic and the Baltic countries.

‘The new agreement is yet another acknowledgement of our industry position and partnership network in the niche specialist and orphan drug area in Europe,' said Martin Nicklasson, chief executive of Swedish Orphan Biovitrum Group.

Cyanokit is indicated for the treatment of known or suspected cyanide poisoning. Administered intravenously, it may be used in an emergency or in hospital, where quick response is critical.

See more

You may also like

Research & Development

Genoskin raises $8.7m in its first funding round to advance its ethical, human-based alternatives to animal testing

Read more
The financing will drive Genoskin’s next phase of growth, with a view to scaling up operations in both the US and France

Trending Articles

  1. Almac expands bioavailability capabilities to address a critical need in drug development Almac Group has completed a multimillion-pound expansion of its bioavailability enhancement capabilities at its facility in Charnwood, UK
  2. Fidia Farmaceutici enters the UK market with the acquisition of Altacor Marking another significant milestone in its ongoing international expansion, the company enters the rapidly growing UK ophthalmology market, a key therapeutic area for the group
  3. Merck scraps £1bn UK expansion amid concerns as warnings mount over UK’s life sciences competitiveness The company cited underinvestment in life sciences and the undervaluation of innovative medicines for the decision, raising questions about the UK’s competitiveness in pharmaceutical research and production
  4. Almac completes a multi-million-pound investment enhancing cold chain capabilities in Craigavon Almac Clinical Services, part of the Almac Group, has completed a multi-million-pound investment to enhance cold chain capabilities at its global headquarters in Craigavon, Northern Ireland
  5. Quintiles invests a further US$14m in China Will also expand lab testing capabilities with SCRC

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Research & Development

Genoskin raises $8.7m in its first funding round to advance its ethical, human-based alternatives to animal testing

The financing will drive Genoskin’s next phase of growth, with a view to scaling up operations in both the US and France
Manufacturing

Sharp boosts autoinjector and pen assembly line capability with $20m investment in Pennsylvania facility

The money will boost its autoinjector and pen assembly, labelling and packaging lines across various therapeutic areas at its facility in Macungie, meeting the rising demand for injectables
Research & Development

Simris Biologics secures €200K funding to develop microcystin-based payloads for antibody-drug conjugates

The Berlin-based subsidiary will use the grant to advance the KlicMic R&D programme, creating targeted microcystin payloads for ADCs that aim to improve cancer therapy efficacy whilst reducing side effects
Research & Development

Merck scraps £1bn UK expansion amid concerns as warnings mount over UK’s life sciences competitiveness

The company cited underinvestment in life sciences and the undervaluation of innovative medicines for the decision, raising questions about the UK’s competitiveness in pharmaceutical research and production
Manufacturing

Almac expands bioavailability capabilities to address a critical need in drug development

Almac Group has completed a multimillion-pound expansion of its bioavailability enhancement capabilities at its facility in Charnwood, UK
Finance

Fidia Farmaceutici enters the UK market with the acquisition of Altacor

Marking another significant milestone in its ongoing international expansion, the company enters the rapidly growing UK ophthalmology market, a key therapeutic area for the group
Packaging

SGD Pharma acquires Alphial Srl in a strategic step forward

SGD Pharma is pleased to announce an agreement with Italian Private Equity firm Entangled Capital to acquire Alphial Srl, a leading producer of tubular vials and ampoules headquartered in Italy
Subscribe now